Boehringer Ingelheim to Mine Ginkgo’s Molecules in $406M Undruggable Targets Deal

Boehringer Ingelheim is mining Ginkgo Bioworks’ bioactive molecules in a deal that could add up to $406 million for the cell programming and biosecurity company.

On Monday, Ginkgo announced BI will leverage its metagenomic sequence database to accelerate the development of novel therapeutics, particularly in diseases considered undruggable with high unmet patient needs. Ginkgo’s metagenomic database now comprises over three terabases of sequence data and more than two billion proprietary protein sequences from a variety of microbes, according to the company.